Workflow
JIANGSU GDK(688670)
icon
Search documents
金迪克:中信证券股份有限公司关于江苏金迪克生物技术股份有限公司2023年半年度持续督导跟踪报告
2023-08-18 07:46
一、持续督导工作情况 1 | 序号 | 工作内容 | 实施情况 | | --- | --- | --- | | | 海证券交易所发布的业务规则及其他规 | 律、法规、部门规章和上海证券交易所 | | | 范性文件,并切实履行其所做出的各项 | 发布的业务规则及其他规范性文件,切 | | | 承诺。 | 实履行其所做出的各项承诺。 | | | 督导上市公司建立健全并有效执行公司 治理制度,包括但不限于股东大会、董 | 保荐机构督促金迪克依照相关规定健全 | | 7 | | 完善公司治理制度,并严格执行公司治 | | | 事会、监事会议事规则以及董事、监事 | 理制度。 | | | 和高级管理人员的行为规范等。 | | | | 督导上市公司建立健全并有效执行内控 | | | | 制度,包括但不限于财务管理制度、会 | 保荐机构对金迪克的内控制度的设计、 | | | 计核算制度和内部审计制度,以及募集 | 实施和有效性进行了核查,金迪克的内 | | 8 | 资金使用、关联交易、对外担保、对外 | 控制度符合相关法规要求并得到了有效 | | | 投资、衍生品交易、对子公司的控制等 | 执行,能够保证公司的规范运行。 ...
金迪克:江苏金迪克生物技术股份有限公司关于临时停产的后续进展公告
2023-08-10 08:26
证券代码:688670 证券简称:金迪克 公告编号:2023-030 流感疫苗车间环境恢复是复产的第一步,目前只是车间恢复到可生产状态, 尚不能进行正式产品的生产。 下一阶段,流感疫苗车间还需要进行模拟试验验证,待模拟试验完成及相 关检测结果检验合格后,流感疫苗车间才可正式恢复生产。 三、其他说明 江苏金迪克生物技术股份有限公司 关于临时停产的后续进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责 任。 一、流感疫苗车间临时停产情况 江苏金迪克生物技术股份有限公司(以下简称"公司")部分车间生产环境 因特大暴雨受到渗水影响,经持续环境监测并综合评估,公司决定自 2023 年 7 月 15 日起流感疫苗车间临时停产。具体内容详见公司于 2023 年 7 月 15 日披露 的《江苏金迪克生物技术股份有限公司关于临时停产的公告》(公告编号: 2023-022)、《江苏金迪克生物技术股份有限公司关于临时停产对经营业绩影响 的补充公告》(公告编号 2023-023)。 二、恢复生产进展情况 公司积极组织人员进行车间环境处理,采取具 ...
金迪克(688670) - 2023 Q2 - 季度财报
2023-08-02 16:00
Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2023, representing a 20% increase compared to the same period last year[11]. - The company's operating revenue for the first half of 2023 reached ¥127,142,761.74, a significant increase of 675.48% compared to ¥16,395,430.84 in the same period last year[16]. - The net profit attributable to shareholders was ¥35,081,003.77, a substantial rise from a loss of ¥17,258,012.55 in the previous year[16]. - Basic and diluted earnings per share were both ¥0.28, compared to a loss of ¥0.14 per share in the same period last year[18]. - The total profit for the first half of 2023 was ¥40,124,558.61, compared to a total loss of ¥11,969,049.69 in the first half of 2022, marking a substantial improvement[187]. - The company's total equity increased to ¥1,477,236,164.38 from ¥1,459,757,258.82, reflecting a growth of about 1.2%[183]. Research and Development - Research and development expenses increased by 30% to RMB 100 million, focusing on the development of new vaccine technologies[11]. - The company's R&D expenditure as a percentage of operating revenue decreased by 138.29 percentage points to 12.10% due to the completion of a major project in 2022[18]. - The total R&D investment decreased by 37.58% year-on-year, amounting to ¥15,390,232.41, with a significant reduction in expense-based R&D investment by 64.99% to ¥6,447,073.81[37]. - The company has a total of 59 R&D personnel, representing 12.91% of the total workforce, an increase from 11.29% in the previous year[43]. - The company is currently developing nine major products targeting five infectious diseases, including influenza, rabies, chickenpox, shingles, and pneumonia[44]. Market Expansion and Strategy - The company has projected a revenue growth of 25% for the second half of 2023, driven by new product launches and market expansion strategies[11]. - The company plans to enter two new international markets by the end of 2023, aiming to increase its global footprint[11]. - A strategic acquisition of a smaller biotech firm was completed, expected to enhance the company's product pipeline and market reach[11]. - The company has established partnerships with three major healthcare providers to enhance distribution channels for its products[11]. - The company has introduced a new vaccine product line, projected to generate an additional RMB 200 million in revenue by the end of 2024[11]. Operational Challenges - The company faced significant operational challenges due to severe flooding, leading to a temporary halt in production and potential revenue loss in Q3 2023[53]. - The company is exploring new product development but faces risks related to the lengthy and complex vaccine R&D process[50]. - The company’s revenue is heavily reliant on the sales of the quadrivalent influenza vaccine, posing risks due to product structure concentration[52]. Environmental and Social Responsibility - The company has invested 470,800 CNY in environmental protection during the reporting period[76]. - The company has implemented measures to manage waste emissions, including a 15m high exhaust stack for waste gas and a wastewater treatment station[77]. - The company has established an emergency response plan for environmental incidents, which has been filed with the environmental authorities[80]. - The company has conducted environmental self-monitoring, with no exceedances reported during the reporting period[81]. - The company has established a dedicated safety and environmental management team to oversee environmental protection and safety production, including the development of an environmental management system and training programs[82]. Shareholder and Governance - All major shareholders and management have committed to a 36-month lock-up period for their shares following the company's IPO, ensuring stability in shareholding[86]. - The company has a policy that limits the annual transfer of shares by directors and senior management to no more than 25% of their total holdings during their tenure and for six months after leaving[88]. - The controlling shareholders emphasize a long-term holding strategy to maintain their controlling position and share in the company's operational results[99]. - The company will strictly adhere to the profit distribution policy as per relevant laws and regulations, adjusting it as necessary in response to regulatory changes[122]. - The company will assume legal responsibility for any false statements or omissions in the prospectus and will repurchase shares if such issues are identified by regulatory authorities[123].
金迪克:江苏金迪克生物技术股份有限公司关于召开2023年半年度业绩说明会的公告
2023-08-02 07:40
证券代码:688670 证券简称:金迪克 公告编号:2023-029 江苏金迪克生物技术股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 会议召开时间:2023 年 9 月 7 日(星期四)下午 15:00-16:00 会议召开地点:上海证券交易所"上证路演中心"网络平台(网址: http://roadshow.sseinfo.com/) (一)召开时间:2023 年 9 月 7 日(星期四)下午 15:00-16:00 1 (二)召开方式:图文展示(可选)+网络文字互动问答 (三)召开地点:上海证券交易所"上证路演中心"网络平台(网址: http://roadshow.sseinfo.com/) 三、参加人员 公司董事长兼总经理余军先生、独立董事管建强先生、财务总监黄强先生、 副总经理兼董事会秘书樊长勇先生。 会议召开方式:图文展示(可选)+网络文字互动问答 投资者可于 2023 年 9 月 6 日(星期三)17:00 前将有关问题通过电子邮 件、 ...
金迪克(688670) - 2022 Q4 - 年度财报
2023-04-19 16:00
Financial Performance - The company's operating revenue for 2022 was ¥318,486,074.97, a decrease of 18.81% compared to ¥392,272,487.50 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥41,544,347.93, down 49.62% from ¥82,460,219.55 in 2021[21]. - The net cash flow from operating activities decreased by 62.86% to ¥38,595,320.99 in 2022, compared to ¥103,925,232.98 in 2021[22]. - The basic and diluted earnings per share for 2022 were both ¥0.47, a decline of 57.27% from ¥1.10 in 2021[23]. - The gross profit margin for the main business was 84.12%, down 1.44 percentage points year-on-year[96]. - The company's sales revenue for 2022 decreased by 73.79 million yuan, a year-on-year decline of 18.81% due to personnel turnover and difficulties in vaccine administration[87]. - The company's total assets at the end of the reporting period were CNY 1.83 billion, an increase of 2.76% from the beginning of the year[94]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was CNY 22.62 million, a decrease of 65.64% year-on-year[94]. Research and Development - The proportion of R&D investment to operating revenue increased by 2.33 percentage points to 14.49% in 2022, compared to 12.16% in 2021[23]. - Research and development expenses (including capitalization) amounted to CNY 46.14 million, focusing on vaccines for major infectious diseases[36]. - The company is currently working on 11 projects with a total expected investment of CNY 240,310,000, with significant progress in several vaccine candidates[75]. - The company has established four core platform technologies for vaccine development, including chicken embryo-based vaccine production technology and cell-based virus culture technology, which support a comprehensive vaccine R&D pipeline[67]. - The company is developing a series of quadrivalent influenza vaccines, including a pediatric version for children under 3 years old and a high-dose version for seniors over 65[82]. - The company has a rich pipeline of 9 major in-development products targeting five significant infectious diseases, which will help maintain strong market competitiveness[82]. Market and Growth Potential - The overall vaccination rate for influenza vaccines in China is approximately 3%, significantly lower than nearly 50% in Europe and the U.S., indicating substantial market growth potential[41]. - The government has implemented policies to promote influenza vaccination, resulting in a vaccination rate of 38% among key populations in regions with free vaccination programs[42]. - The global vaccine market size was $30.5 billion in 2018, accounting for 3.5% of the global pharmaceutical market, and is projected to reach $44.8 billion by 2024, with a compound annual growth rate (CAGR) of 6.6%[52]. - In China, the vaccine market revenue was approximately ¥331.7 billion in 2018, expected to grow to ¥1,017.7 billion by 2023, reflecting a CAGR of 25.1%[54]. - The market for second-class vaccines in China grew from $1.3 billion in 2016 to $7.6 billion in 2021, maintaining a CAGR of around 40%, and is projected to reach $9.5-10 billion by 2028[56]. Corporate Governance - The company has received a standard unqualified audit report from Da Hua Certified Public Accountants, ensuring the accuracy of its financial statements[4]. - There are no non-operating fund occupations by controlling shareholders or related parties, indicating a stable financial governance structure[7]. - The company has not violated any decision-making procedures regarding external guarantees, reinforcing its compliance with regulations[8]. - The report emphasizes the importance of reviewing the "Management Discussion and Analysis" section for insights into risk factors and operational challenges[4]. - The company has not disclosed any special arrangements for corporate governance, suggesting a standard governance framework[8]. Risk Factors - The company has detailed various operational risks in the report, which investors should review for potential impacts on future performance[4]. - The report includes a forward-looking statement risk disclaimer, cautioning investors about the uncertainties in future plans and strategies[6]. - The company is currently facing risks related to core technology leakage, new product development delays, and uncertainties in commercialization of in-development products[88]. Environmental and Social Responsibility - The company invested approximately 2.46 million RMB in environmental protection during the reporting period[189]. - The company has established a comprehensive environmental management system to ensure compliance with environmental laws and regulations[188]. - The company produced major pollutants including wastewater, waste gas, and solid waste, with specific treatment measures in place[191]. - The company has implemented a robust internal control system to ensure effective governance and compliance with laws and regulations[185]. Employee and Management Structure - The total number of employees at the parent company is 474, with 226 in production, 32 in sales, 180 in technology, 10 in finance, and 26 in administration[169]. - The company has a competitive salary system and benefits to ensure a win-win situation for both corporate performance and employee earnings[171]. - The company provides comprehensive training programs aimed at enhancing employees' skills in pharmaceutical and quality management, as well as management skills and professional qualities[172]. - The company has established a robust R&D innovation system that does not rely heavily on individual technical personnel, ensuring normal operations and future development capabilities[80].
金迪克(688670) - 2023 Q1 - 季度财报
2023-04-19 16:00
Financial Performance - The company's revenue for Q1 2023 reached ¥106,219,935.77, representing a significant increase of 751.94% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥36,346,153.06, with a substantial growth attributed to increased sales during the quarter[5][8]. - The basic and diluted earnings per share for the quarter were both ¥0.41, reflecting the company's strong performance[6]. - In Q1 2023, the company reported a net profit of CNY 36,346,153.06, a significant recovery from a net loss of CNY 2,641,751.10 in Q1 2022, marking a turnaround of over 1,400%[19]. - Operating profit for Q1 2023 was CNY 41,239,941.04, compared to an operating loss of CNY 281,074.90 in the same period last year[19]. - The company’s total profit for Q1 2023 was CNY 40,748,976.62, compared to a loss of CNY 270,416.31 in the same quarter last year[19]. Revenue and Costs - Total operating revenue for Q1 2023 reached RMB 106,219,935.77, a significant increase from RMB 12,468,040.78 in Q1 2022, representing a growth of approximately 752.5%[18]. - Total operating costs for Q1 2023 were RMB 74,836,834.78, compared to RMB 21,145,299.52 in Q1 2022, indicating an increase of about 353.5%[18]. - Total revenue from sales of goods and services reached CNY 94,157,637.00, up from CNY 80,436,361.90 in Q1 2022, representing an increase of approximately 17.5%[22]. Cash Flow and Assets - The net cash flow from operating activities was ¥6,437,234.74, showing a growth of 4.94% compared to the previous year[5]. - The company's cash and cash equivalents as of March 31, 2023, amounted to RMB 265,761,691.20, up from RMB 174,728,926.82 at the end of 2022, reflecting a growth of approximately 52.0%[14]. - Cash and cash equivalents at the end of Q1 2023 totaled CNY 265,761,691.20, a substantial increase from CNY 116,257,683.14 at the end of Q1 2022, reflecting a growth of over 128%[23]. - The company generated a net cash flow from operating activities of CNY 6,437,234.74, slightly up from CNY 6,134,019.46 in Q1 2022[22]. - Investment activities generated a net cash inflow of CNY 78,018,421.33, compared to CNY 63,593,297.03 in Q1 2022, indicating a growth of approximately 22.6%[23]. Shareholder Information - The company reported a total of 4,729 common shareholders at the end of the reporting period[10]. - The top two shareholders, Yu Jun and Zhang Liangbin, each hold 30.74% of the shares, totaling 27,049,291 shares[10]. Research and Development - Research and development expenses totaled ¥6,559,451.54, accounting for 6.18% of revenue, a decrease of 38.92 percentage points year-on-year[6]. - The company reported an increase in research and development expenses to CNY 3,100,291.99 from CNY 2,949,671.40 in the previous year, reflecting a commitment to innovation[19]. Assets and Liabilities - Total assets at the end of the quarter were ¥1,877,139,584.80, an increase of 2.76% from the end of the previous year[6]. - Total assets as of March 31, 2023, were RMB 1,877,139,584.80, compared to RMB 1,826,776,950.09 at the end of 2022, marking an increase of approximately 2.8%[16]. - Total liabilities as of March 31, 2023, amounted to RMB 381,121,533.52, up from RMB 367,105,051.87 at the end of 2022, indicating a growth of about 3.0%[16]. - The company's non-current assets totaled RMB 881,896,549.21 as of March 31, 2023, slightly increasing from RMB 875,761,410.71 at the end of 2022, reflecting a growth of approximately 0.1%[15]. Market Demand - The company experienced a surge in demand for flu vaccines due to a high incidence of flu in multiple regions, contributing to the sales growth[8]. Other Information - The company has not disclosed any new product launches or technological advancements during this reporting period[12]. - There are no significant mergers or acquisitions reported in the current quarter[12]. - The company's financial expenses decreased significantly, with interest expenses reported at CNY 428,300.02, compared to CNY 166,249.99 in Q1 2022[19].
金迪克:江苏金迪克生物技术股份有限公司关于召开2022年年度业绩说明会的公告
2023-04-13 08:30
证券代码:688670 证券简称:金迪克 公告编号:2023-005 江苏金迪克生物技术股份有限公司 关于召开 2022 年年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 会议召开地点:上海证券交易所"上证路演中心"网络平台(网址: http://roadshow.sseinfo.com/) 会议召开方式:网络文字互动方式 投资者可于 2023 年 4 月 20 日(星期四)17:00 前将有关问题通过电子 邮件、传真的形式发送至公司邮箱 gdk001@gdkbio.com。公司将在业绩说明会 上对投资者普遍关注的问题进行回答。 江苏金迪克生物技术股份有限公司(以下简称"公司")将于 2023 年 4 月 20 日在《上海证券报》、《中国证券报》、《证券时报》、《证券日报》及上海证券 交易所网站(www.sse.com.cn)披露《江苏金迪克生物技术股份有限公司 2022 年年度报告》及其摘要。为便于广大投资者更加全面、深入地了解公司 2022 年 年度经营成果、财务状况,在上海证券交易所的支持下,公 ...
金迪克(688670) - 投资者关系活动记录表2022-002
2022-11-19 03:38
证券代码:688670 证券简称:金迪克 (2022 年 4 月) 1 江苏金迪克生物技术股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |-----------------------|-------------------------------------|--------------------------------------------------|--------------------------|----------------------------------------------|----------------------| | 投资者关系活 \n动类别 | □ 特定对象调研 □ \n□ 业绩说明会 □ | 分析师会议 □ \n路演活动 □ | 媒体采访 \n现场参观 | 编号: □ 新闻发布会 \n √ 电话会议 | 2022-002 \n □ 其他: | | | 姓名 公司 | | | | | | | 杨松 | 天风证券 | | | | | | 李妞妞 | 天风证券 | | | | | | 袁维 | 国金证券 | ...
金迪克(688670) - 投资者关系活动记录表2022-003
2022-11-17 14:42
编号:2022-003 1 证券代码:688670 证券简称:金迪克 江苏金迪克生物技术股份有限公司 投资者关系活动记录表 (2022 年 6 月) | --- | --- | --- | --- | --- | --- | |-----------------------|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|-------------------------|-------------| | 投资者关系活 \n动类别 | □ 特定对象调研 \n□业绩说明会 | □分析师会议 \n□路演活动 | □ 媒体采访 \n□ 现场参观 | □新闻发布会 \n√电话会议 | □ 其他: | | 参与单位名称 | 见附件 | | | | | ...
金迪克(688670) - 2022 Q2 - 季度财报
2022-08-05 16:00
Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a 20% increase compared to the same period last year[12]. - The company's revenue for the first half of 2022 was ¥16,395,430.84, a decrease of 48.91% compared to ¥32,094,226.23 in the same period last year[19]. - The net profit attributable to shareholders was -¥17,258,012.55, an improvement from -¥23,305,052.08 in the previous year[19]. - The net cash flow from operating activities decreased by 65.79%, amounting to ¥23,713,108.47 compared to ¥69,322,947.23 last year[19]. - The company's total assets decreased by 6.05% to ¥1,648,408,667.31 from ¥1,754,489,818.27 at the end of the previous year[20]. - The basic and diluted earnings per share were both -¥0.20, compared to -¥0.35 in the same period last year[20]. - The weighted average return on net assets improved to -1.20% from -10.10% in the previous year[20]. - In the first half of 2022, the company's operating revenue was 16.40 million yuan, a year-on-year decrease of 48.91%, and the net profit attributable to the parent company was -17.26 million yuan, a year-on-year reduction in losses of 6.05 million yuan[53]. - The company achieved operating revenue of CNY 16,395,430.84, a year-on-year decrease of 48.91%[67]. - The net profit attributable to the parent company was CNY -17,258,000, a year-on-year improvement of CNY 6,047,000[67]. Research and Development - The R&D expenditure as a percentage of revenue increased by 62.86 percentage points to 150.39% from 87.53% in the previous year[20]. - The total R&D investment for the reporting period was CNY 24,656,502.60, a decrease of 12.23% compared to the previous year, with a significant increase in the ratio of R&D investment to operating income from 87.53% to 150.39%[39]. - The company has a total of 49 R&D personnel, an increase from 42 in the previous year, with R&D personnel accounting for 11.29% of the total workforce[43]. - The average salary of R&D personnel increased to CNY 6.91 million from CNY 6.25 million in the previous year[43]. - The company is developing a quadrivalent influenza virus split vaccine, with a total investment of CNY 33 million, currently in Phase I clinical trials[40]. - The company has achieved significant progress in the development of a 23-valent pneumococcal polysaccharide vaccine, which is currently in the preclinical research stage[40]. - The company has built four core technology platforms for vaccine development, enhancing its ability to produce various viral and bacterial vaccines[32]. - The company has established a comprehensive formulation production technology platform covering various vaccine dosage forms, which will support the R&D and industrialization of other vaccine formulations[36]. - The company has received a total of 23 intellectual property applications, with 12 granted, including 2 invention patents and 10 utility model patents[36]. Market Expansion and Strategy - User data indicates that the company has expanded its customer base by 15%, reaching a total of 1.2 million active users[12]. - The company is exploring market expansion opportunities in Southeast Asia, aiming to enter three new countries by the end of 2022[12]. - A strategic acquisition of a local biotech firm was completed, enhancing the company's R&D capabilities and expected to contribute an additional RMB 100 million in revenue[12]. - The company has established a marketing network of over 2,000 county-level disease control centers across 29 provinces, laying a solid foundation for future brand development and market expansion[31]. - The company plans to increase its marketing budget by 30% to enhance brand visibility and customer engagement[12]. - A new partnership with a leading healthcare provider is expected to drive sales growth by improving distribution channels[12]. Financial Management and Investments - The company raised a total of 1,213,960,000.00 CNY through its initial public offering, with a net amount of 1,135,676,130.00 CNY after deducting issuance costs[160]. - The total committed investment amount for the raised funds is 1,600,000,000.00 CNY, with an adjusted total of 1,135,676,130.00 CNY[160]. - As of the end of the reporting period, the cumulative investment amount reached 938,113,326.08 CNY, representing an investment progress of 82.60%[160]. - The company invested 124,686,137.07 CNY in the current year, accounting for 10.97% of the total committed investment[160]. - The company has implemented high standards for quality control, ensuring that the quality of its quadrivalent influenza virus split vaccine exceeds national and European pharmacopoeia standards[55]. Compliance and Governance - The company has committed to a 36-month lock-up period for major shareholders, during which they cannot transfer or manage their shares[97]. - The company emphasizes compliance with relevant laws and regulations regarding share transfers by major stakeholders[100]. - The company has established commitments to resolve related party transactions and competition issues among its executives[96]. - The company will continue to follow the guidelines set forth in the IPO prospectus regarding shareholding commitments and reductions[111]. - The company commits to maintaining the legitimate rights and interests of all shareholders and will not transfer benefits to other entities or individuals under unfair conditions[126]. Environmental Responsibility - The company has implemented various pollution control measures, including the use of natural gas for waste gas treatment and a wastewater treatment station to ensure compliance with environmental standards[83]. - The company has established an emergency response plan for environmental incidents and conducts regular training to enhance staff crisis management capabilities[87]. - The company is committed to energy conservation and pollution prevention, integrating these principles into daily operations[92].